Singular Genomics Systems, Inc. Stock Price, News & Analysis

Singular Genomics Systems (Nasdaq: OMIC) announced new data validating the performance and versatility of its G4 Sequencing Platform during the AGBT 2023 meeting. This dataset, collected from 11 renowned genomics partners, showcases the platform's high accuracy and adaptability across various applications. Partners include industry leaders like 10x Genomics and QIAGEN. The data suggests that the G4 integrates seamlessly into existing NGS workflows, enhancing speed and flexibility in sequencing tasks. Although the company has ambitious commercialization goals, potential risks remain concerning developing and competing with other products.

Singular Genomics Systems, Inc. (Nasdaq: OMIC) has launched the Max Read™ Kits for single cell applications on its G4 Sequencing Platform at the AGBT 2023 meeting. The kits allow for a market-leading output of 3.2 billion reads per run, priced at $1 per million reads. The G4 platform has increased its flow cell specifications to achieve 80–90% Q30 quality, with throughput now reaching up to 450 million reads for F3 flow cells. The company anticipates shipping to customers in Q2 2023 and aims for the G4 to become the leading benchtop system for single cell applications.

Singular Genomics Systems, Inc. (NASDAQ: OMIC) announced that its G4 Sequencing Platform is now compatible with the 10x Genomics Chromium Single Cell platform through the Compatible Partner Program. This partnership promises enhanced performance for customers, ensuring faster, more accurate, and cost-effective single-cell sequencing results. Jorge Velarde emphasized the G4's flexibility and scalability, while 10x Genomics recognized its accuracy. Additionally, the press release includes forward-looking statements regarding potential revenue and market challenges, highlighting a competitive landscape and the need for strong market acceptance of their products.

Singular Genomics Systems (Nasdaq: OMIC) announced the shipment of five G4 instruments and preliminary fourth-quarter 2022 revenue of approximately $700,000. The revenue reflects only those instruments meeting recognition criteria. CEO Drew Spaventa emphasized the company’s operational success in Q4 and plans for 2023, focusing on scaling production and expanding the customer base. Full financial results for Q4 and 2022 will be disclosed in March 2023.

Singular Genomics Systems (Nasdaq: OMIC) announced its participation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12, 2023, at 10:30 a.m. PT. The company will showcase its innovative next-generation sequencing and multiomics technologies, aiming to empower researchers and clinicians in advancing science. Investors can access a live and recorded webcast of the presentation via the company’s investor relations website.

Singular Genomics Systems (Nasdaq: OMIC) reported its third quarter 2022 financial results, revealing a net loss of $23.8 million or $0.33 per share, compared to a loss of $17.6 million or $0.25 per share in Q3 2021. Operating expenses rose to $24.7 million from $17.5 million, largely due to an expanded workforce to support growth and the G4 system launch. The company remains on track to ship G4 systems in Q4 2022 and has engaged in partnerships for library prep validation, enhancing customer outreach.

Singular Genomics Systems, Inc. (Nasdaq: OMIC) will release its third quarter 2022 financial results on November 7, 2022. A conference call with management is scheduled for 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to discuss these results. The company specializes in next-generation sequencing (NGS) and multiomics technologies, offering the G4 Sequencing Platform, a benchtop sequencer designed for speed and accuracy, along with the development of the PX system for in-situ analysis of RNA and proteins at the single-cell level.

Singular Genomics Systems, Inc. (Nasdaq: OMIC) has updated the time for its presentation at the Inaugural Gilmartin Group Emerging Growth Company Showcase. The presentation is now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022. Interested parties can register and access a live webcast of the event via a provided link. Singular Genomics is focused on developing next-generation sequencing and multiomics technologies, including the G4 Sequencing Platform, designed to deliver fast and accurate genomic results.

Singular Genomics Systems, Inc. (Nasdaq: OMIC) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually on August 31, 2022, at 7:30 a.m. PT / 10:30 a.m. ET. The event will feature a presentation by Singular Genomics' management, and interested parties can register for a live webcast. The company specializes in next-generation sequencing (NGS) and multiomics technologies, aiming to empower researchers and clinicians with its G4 Sequencing Platform and developing PX system.